miR-184 represses β-catenin and behaves as a skin tumor suppressor.

Autor: Turovsky L; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel.; Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel., Kheshaiboun G; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel.; Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel., Yassen G; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel., Nagosa S; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel., Boyango I; Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel., Amitai-Lange A; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel., Bhattacharya S; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel., Ilan N; Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, 31096, Israel., Vlodavsky I; Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, 31096, Israel., Aberdam D; Université de Paris Cité, INSERM U1138, Centre des Cordeliers, Paris, France., Shalom-Feuerstein R; Department of Genetics & Developmental Biology, The Rappaport Faculty of Medicine & Research Institute, Technion Integrated Cancer Center, Technion - Israel Institute of Technology, Haifa, 31096, Israel., Avitan-Hersh E; Skin Cancer Research lab, Clinical research institute (CRIR), Rambam Health Care Campus, Haifa, 31096, Israel. emily@technion.ac.il.; Cell Biology and Cancer Science, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Integrated Cancer Center, Technion Israel Institute of Technology, Haifa, 31096, Israel. emily@technion.ac.il.
Jazyk: angličtina
Zdroj: Cell death & disease [Cell Death Dis] 2024 Feb 26; Vol. 15 (2), pp. 174. Date of Electronic Publication: 2024 Feb 26.
DOI: 10.1038/s41419-024-06554-4
Abstrakt: miR-184-knockout mice display perturbed epidermal stem cell differentiation. However, the potential role of miR-184 in skin pathology is unclear. Here, we report that miR-184 controls epidermal stem cell dynamics and that miR-184 ablation enhances skin carcinogenesis in mice. In agreement, repression of miR-184 in human squamous cell carcinoma (SCC) enhances neoplastic hallmarks of human SCC cells in vitro and tumor development in vivo. Characterization of miR-184-regulatory network, suggests that miR-184 inhibits pro-oncogenic pathways, cell proliferation, and epithelial to mesenchymal transformation. Of note, depletion of miR-184 enhances the levels of β-catenin under homeostasis and following experimental skin carcinogenesis. Finally, the repression of β-catenin by miR-184, inhibits the neoplastic phenotype of SCC cells. Taken together, miR-184 behaves as an epidermal tumor suppressor, and may provide a potentially useful target for skin SCC therapy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: